Compare Amphastar Pharmaceuticals Inc (AMPH) vs Nutanix Inc (NTNX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Nutanix Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.83 (market cap $868.62M), while Nutanix Inc trades at $64.39 (market cap $17.39B). The key difference: Nutanix Inc is far larger — about 20× Amphastar Pharmaceuticals Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | NTNX | |
|---|---|---|
Market Cap | $868.62M | $17.39B |
Sector | Health | Technology |
52-Week High | $30.81 | $81.12 |
52-Week Low | $16.87 | $34.41 |
Enterprise Value | $1.27B | $16.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $19.87, down 2.19% today, with a bullish technical signal from moving averages and ADX indicators. The company reported Q2 2026 EPS of $0.91, beating expectations, but missed in Q4 2025 and Q1 2026. Revenue for 2025 was $719.89M with a net income margin of 10.76%, while valuation ratios like P/E of 12.08 and EV/EBITDA of 6.57 suggest reasonable pricing. Recent news highlights growth from new product launches and ongoing FDA compliance efforts.
The outlook is mixed with growth opportunities from proprietary drugs and biosimilars, but risks include regulatory scrutiny and earnings volatility. Analyst sentiment is cautious with 25% buy ratings, reflecting concerns over execution and market pressures. Investors should weigh solid cash flow generation against competitive and regulatory headwinds for balanced exposure.
Nutanix (NTNX) trades at $64.32, down 0.22% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $0.47 surpassing the $0.36 expectation. Revenue grew to $2.54B in 2025 with a net income margin of 7.42%, while 2026 projections show improved profitability. Analyst sentiment remains positive with 20 buy ratings and a $57.80 consensus price target.
The outlook for NTNX is supported by strong earnings momentum and institutional interest, though high valuation multiples (P/E 67.71) and supply chain risks noted in recent news pose challenges. The stock's proximity to resistance at $65.00 suggests near-term consolidation may occur before further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Nutanix Inc
Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →
